Medivir to present data from its Cathepsin S inhibitor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Medivir to present data from its Cathepsin S inhibitor program including MIV-247 for neuropathic pain, at the 15th World Congress on Pain

Stockholm, Sweden – Medivir AB (OMX:MVIR) announces that data from its cathepsin S inhibitor drug development program for neuropathic pain will be presented at “The 15th World Congress on Pain in Buenos Aires. The poster presentations will include the preclinical profile of MIV-247, selected as a clinical candidate for further development, and preclinical results from combination treatments with a cathepsin S inhibitor and gabapentin, a commonly used drug for neuropathic pain. The data to be presented support the development of a potent oral cathepsin S inhibitor such as MIV-247 as a new treatment for neuropathic pain: · Use in first line monotherapy – cathepsin S inihibition provided fast and sustained effects in neuropathic pain models · Use as an add-on to current treatments - markedly enhanced efficacy was seen when a cathepsin S inhibitor was given in combination with gabapentin compared to either drug alone · Low side effect potential - No CNS side effects were seen at the highest efficacious dose “We are very excited about these promising data, which provide support for a potential new efficacious and safe treatment option for the many patients which are suffering from chronic neuropathic pain and in whom current treatments are ineffective or poorly tolerated because of their side effects. The findings that addition of a cathepsin S inhibitor to current standard treatment could enhance the efficacy also opens for the potential to decrease doses of the companion drug and hence their side effects,” says Charlotte Edenius, EVP Development at Medivir AB. Data to be presented at the 15th World Congress on Pain in Buenos Aires include: Poster Presentations: Thursday, October 9, 2014 8:00 AM - 5:00 PM: PH346: MIV-247 - A cathepsin S protease inhibitor developed as a novel therapy for neuropathic pain PH099: Cathepsin S inhibition enhances the anti-allodynic effects of gabapentin in a model of neuropathic pain For more information please visit www.iasp-pain.org. Neuropathic pain Neuropathic pain is caused by a trauma or disease affecting the nervous system such as diabetes, shingles, cancer or chronic lower back pain. Currently marketed drugs have limited efficacy and poor side-effect profiles. Patients with neuropathic pain are therefore in great need of new and efficacious therapies that can deliver sustainable pain relief with improved tolerance and adverse event profiles. Neuropathic pain affects approximately 30 million patients across the US, Europe and Japan. In 2013 the overall global sales in neuropathic pain market was 6 BUSD with the largest product being pregabalin: 1.8 BUSD*. MIV-247 - a Cathepsin S inhibitor for Neuropathic Pain MIV-247 is a potent and highly selective inhibitor of cathepsin S. Cathepsin S is a protease which has been shown to be important for the maintenance of the neuropathic pain state, through its action in releasing membrane-bound fractalkine (a pro-inflammatory peptide) from the surface of neurons. Fractalkine is a potent chemokine which stimulates the recruitment of inflammatory cells to the sites of neuronal damage and activates microglia. These cells are implicated as key drivers in the pathogenesis of chronic neuropathic pain. The inhibition of cathepsin S results in reduced pain related behavior in preclinical models of neuropathic pain. For further information, please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292. About Medivir Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. Medivir receives royalties from Johnson & Johnson’s global sales of the hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseases, osteoarthritis, neuropathic pain and oncology. Medivir is listed on the Nasdaq OMX Stockholm Mid Cap List. *Decision Resource 2013

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 47

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 100

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 0

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 109

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 16

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 44

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 88

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Dining and Shopping Experiences Coming to Cotino

Updated Category News Views 309

Exciting Developments at Cotino Bay Beach A vibrant new community is set to emerge with the opening of Cotino Bay Beach, Dining and Shops in fall 2026. The first Storyliving by Disney community is gearing up to offer an array of dining and retail experiences, creating a unique destination for residents and visitors alike. Restaurants to Enrich the Community Among the...

Continue Reading
dsm-firmenich Expands Share Repurchase Program for Growth

Updated Category News Views 227

Introduction to the Share Repurchase Program dsm-firmenich, a leader in nutrition, health, and beauty, has embarked on a significant share repurchase program with the aim of enhancing shareholder value and strategically managing its capital. By initiating this buyback, dsm-firmenich demonstrates its commitment to returning value to its investors while still investing in...

Continue Reading
Investigation into Arvinas, Inc. Over Securities Fraud Claims

Updated Category News Views 561

Investigation of Arvinas, Inc. Pomerantz LLP is looking into potential claims on behalf of investors of Arvinas, Inc. (NASDAQ: ARVN). This investigation aims to uncover whether the company and its executives may have engaged in securities fraud or other illegal business practices. Recent Developments Arvinas has recently communicated significant changes to its clinical...

Continue Reading
Gantry Enhances Mortgage Banking with Triad Capital Acquisition

Updated Category News Views 145

Gantry got its hands on Triad Capital Advisors back in 2023, and it was no small move. This merger wasn't just about beefing up their operational muscle; it expanded Gantry's footprint in the Midwest finance scene big time. It’s like they dropped a bomb on their competitors without warning—traders watching closely could feel the shift coming. With this acquisition,...

Continue Reading
Port Athena Debuts with PENETRON Solution in Tartu

Updated Category News Views 32

The Emergence of Port Athena in Tartu Move over, sleepy towns—Tartu's staking its claim with the Port Athena development. What we're looking at is more than just another block of buildings. It's practically a new district, nestled on the banks of the Emajõgi River. Forget the stereotypical old-world charm; we're talking sleek, modern architecture that's ready to become...

Continue Reading